# US 2026/0062431 A1 · Silicon-incorporated hdac-6 inhibitor for liver and lung fibrotic disorder

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0062431 A1
- Document ID: US20260062431A1
- Status: Published application
- Kind: A1
- Application number: 19/199,624
- Filed: 2025-05-06
- Published: 2026-03-05
- Earliest claimed: 2024-09-05
- Applicants: Council of Scientific and Industrial Research
- Inventors: Dumbala Srinivasa REDDY; Sai Balaji ANDUGULAPATI; Laxman Devappa NANDAWADEKAR; Ramesh EAGALA; Nidhi SHARMA; Ganesh ROUTHOLLA; Hari Priya SRIPADI
- Web page: https://patentgrep.com/patent/US20260062431A1

## CPC

- C07F 7/0816: {said ring comprising Si as a ring atom}
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

The present invention discloses silicon-incorporated HDAC-6 inhibitors of formula (I) and the process of preparation thereof. The invention further relates to methods of treating a group consisting of idiopathic pulmonary fibrosis, hepatic fibrosis, and other fibrotic disorders such as cardiac, kidney, and skin fibrosis.

## Claims

### Claim 1

A silicon-incorporated HDAC 6 inhibitor compound of formula (I)
wherein,
n is selected from 0-4;
R1 is selected from the group consisting of hydrogen, halogen, C1-C5 alkyl, C1-C5 alkoxy;
R2 and R5 are independently selected from the group consisting of C1-C3 alkyl, aryl groups;
R4 is selected from the group consisting of hydroxy, NH2, C1-C12 alkyl amine, substituted aryl amine and a mixture thereof.

### Claim 2 (depends on 1)

The silicon-incorporated HDAC 6 inhibitor compounds of formula (I) according to claim 1, wherein the compounds are selected from the group comprising:

### Claim 3 (depends on 1)

The silicon-incorporated HDAC 6 inhibitor compounds according to claim 1, wherein the compound attenuate the extracellular matrix proteins and collagen markers expression in TGF-β stimulated LL29 cells for idiopathic pulmonary fibrosis (IPF) and liver fibrosis.

### Claim 4 (depends on 1)

The silicon-incorporated HDAC-6 inhibitory compound of formula (V) according to claim 1,
wherein,
n is 0, 1, 2, 3, 4;
m is 1-12;
R1 is selected from the group consisting of hydrogen, halogen, C1-C5 alkyl, and C1-C5 alkoxy; and
R2 and R3 are independently selected from the group consisting of C1-C3 alkyl, aryl groups.

### Claim 5 (depends on 1)

The silicon-incorporated HDAC 6 inhibitory compound of formula (VIII) according to claim 1,
wherein,
n is 0, 1, 2, 3, 4;
R1 is selected from the group consisting of hydrogen, halogen, C1-C5 alkyl, and C1-C5 alkoxy; and
R2 and R3 are independently selected from the group consisting of C1-C3 alkyl, aryl groups.

### Claim 6 (depends on 4)

A process for the preparation of silicon-incorporated HDAC 6 inhibitor compounds of formula (V) according to claim 4, comprising the steps of:
a) reacting a compound of formula (III) with a hydrazine hydrate at a temperature of 100° C. for the period of 3 to 5 hrs to obtain a compound of formula (IV)
b) reacting the compound of formula (IV) obtained in step a) with a C1-C12 alkyl aldehyde at an ambient temperature period of 2 to 3 hrs followed by reacting with a reducing agent to prepare a compound of formula (V)

### Claim 7 (depends on 5)

A process for the preparation of silicon-incorporated HDAC 6 inhibitor compounds of formula (VIII) according to claim 5, comprising the steps of:
a) reacting a compound of formula (III) with a base in presence of a polar solvent for time period of 16 hours to obtain a compound of formula (VI)
b) reacting the compound of formula (VI) obtained in step a) with a substituted aryl amine in presence coupling reagent and a base in a polar solvent for a time period of 16 hours followed by an acid treatment to obtain a compound of formula (VIII)

### Claim 8 (depends on 6)

The process according to claim 6, wherein the C1-C12 aldehyde in step b) is selected from the group consisting of propionaldehyde, butyraldehyde, pentanal, heptanal, heptaldehyde, octanal, undecanal, dodecanal, benzaldehyde, 3-propylbenzaldehyde, and 4-propylbenzaldehyde.

### Claim 9 (depends on 6)

The process according to claim 6, wherein the reducing reagent in step b) is selected from the group consisting of NaBH4 (sodium borohydride), NaCNBH4 (sodium cyanoborohydride), and STAB (sodium triacetoxyborohydride) or a mixture thereof.

### Claim 10 (depends on 7)

The process according to claim 7, wherein the base in step a) is selected from the group consisting of NaOH (sodium hydroxide), LiOH (lithium hydroxide), and KOH (potassium hydroxide).

### Claim 11 (depends on 7)

The process according to claim 7, wherein the substituted aryl amine in step b) is selected from the group consisting of aniline, 2-amino aniline, 3-amino aniline, 4-amino aniline, 2-aminophenol, 4-aminophenol, 4-nitroaniline, 2-nitroaniline 4-aminobenzonitrile, 2-aminobenzonitrile, 3-aminobenzonitrile, 3-ethylaniline, 3-fluoroaniline, 3-bromooaniline, 2,5-dibromoaniline, 2-methoxyaniline, and 4-methoxyaniline

### Claim 12 (depends on 7)

The process according to claim 7, wherein the coupling agent in step b) is selected from the group consisting of hexafluorophosphate azabenzotriazole tetramethyl uronium (HATU), hydroxybenzotriazole (HOBt), 1-rthyl-3-(3-dimethylaminopropyl) carbodiimide (EDC·HCl), N,N′-dicyclohexylcarbodiimide (DCC), hexafluorophosphate benzotriazole tetramethyl uronium (HBTU), propanephosphonic acid anhydride (T3P) or a mixture thereof.

### Claim 13 (depends on 7)

The process according to claim 7, wherein the base in step b) is selected from the group consisting of diisopropylethylamine (DIPEA), triethyl amine (TEA), and 4-(N,N-dimethylamino)pyridine (DMAP) or a mixture thereof.

### Claim 14 (depends on 7)

The process according to claim 7, wherein the polar solvent in step a) and step b) is selected from the group consisting of methanol, ethanol, THF (tetrahydrofuran), DMF (dimethylformamide), DCM (dichloromethane), aqueous alcohol or a mixture thereof.

### Claim 15 (depends on 7)

The process according to claim 7, wherein the acid in step b) is selected from the group consisting of hydrochloric acid (HCl), trifluoroacetic acid (TFA), methanesulfonic acid (MSA), para-toluene sulfonic acid (PTSA) or a mixture thereof.

### Claim 16 (depends on 1)

The silicon-incorporated HDAC 6 inhibitor compounds of formula (I) according to claim 1, wherein use of silicon incorporation pyridoindole HDAC inhibitory compounds and isomer, derivative, racemate, analogue and/or pharmaceutically acceptable salt form is for preparation of different drugs/APIs/alkaloids.

### Claim 17 (depends on 1)

The silicon-incorporated HDAC 6 inhibitor compounds of formula (I) according to claim 1, wherein the silicon incorporation pyridoindole HDAC inhibitory compounds and isomer, derivative, racemate, analogue and/or pharmaceutically acceptable salt form are therapeutic agent for treating idiopathic pulmonary, hepatic, cardiac, kidney, and skin fibrosis.
